You may have seen that the CDC and its Advisory Committee on Immunization Practices (ACIP) has updated/changed their guidelines on patient’s with egg allergy. Here is a brief overview of the new recommendations or click the link to read them on the CDC’s website:
1. They no longer recommend a 30 min observation period after receiving the vaccine for egg allergic patients.
2. The vaccine can be administered in an inpatient or outpatient medical setting (which does not exclude retail pharmacy locations).
3. Any vaccine may be used so long as it is appropriate for age and health status.
4. Patients who have a reaction more severe than hives such as respiratory distress, recurrent vomiting, etc. OR who required epinephrine or “other emergency medicine intervention” may be given the vaccine in an outpatient setting by a medical professional trained to recognize and manage severe allergic reaction.
5. Severe reaction to a previous vaccine is a contraindication for receiving future vaccines.
I should have posted this a while ago but became side tracked with my Food Free Trunk or Treat events. I still feel it is pertinent although a bit late; the level of sarcasm is strong with this one…
As we know, Mylan has agreed to pay $465 Million as part of a Department of Justice Settlement for wrongly classifying EpiPen as a generic product. The generic classification allowed the company to pay substantially less in Medicare/Medicaid rebates: “Drugmakers are required by law to pay rebates for sales to patients insured by Medicaid, which is funded jointly by states and the federal government. By classifying EpiPen as a generic, Mylan paid a smaller rebate of 13%, or about $163 million, when it should have been paying a 23% or higher rebate for brand-name drugs, Mr. Slavitt wrote” as noted in the WSJ. It’s too bad the average American consumer isn’t privy to those lucrative rebates–but I digress.
Senator Amy Klobuchar (D.-Minn.) described the mis-classification as an “outrage.” And yes, we should be outraged…but not solely at Mylan.
Why does EpiPen not have a market competitor? The answer in one acronym: the FDA.
And the insanity surrounding EpiPen continues to make my head spin.
#EPIGATE has taken the media and the allergy community by storm over the last week. Heather Bresch, CEO of Mylan, discussed the “broken system” on CNBC yesterday. We all know that the price of EpiPen is outrageous. But why? Is it all Mylan’s fault?
In the pharmacy we notice that people become very confused when it comes to the language health care providers use when discussing payment. Hopefully this post will help clear up some confusion… Continue reading
I recently had a bit of info on Fenugreek brought to my attention via the Facebook page; so I decided to do a little digging. The “little digging” turned into something a bit bigger… Continue reading
A few days (more like weeks now) ago, I had to get re-certified in CPR. As I was going through the process of watching the American Heart Association‘s BLS, or Basic Life Support, videos and practicing technique, two things really struck me: Continue reading
Ok, well, some people already knew.
I was amazed today–amazed at a website that can help so many people BUT not one single pharmacist that I speak with on a regular basis had even heard of. How does this happen? Seriously, HOW? Continue reading
Happy New Year!!
I want this year to be a year of transformation. I have resolved to be a healthier version of myself (focusing a bit more on me for a change–specifically health wise) and I have resolved to be a better advocate.
To be honest, I don’t like to write. I’m not a writer; heck I don’t even consider myself a blogger. Continue reading
While traveling with E and A today, I visited one of Cracker Barrel‘s 600 locations. E has never eaten at the Cracker Barrel but since so many restaurants have embraced the challenges of providing for allergic customers I thought I would give it a go. Welp…a half hour (and 3 bathroom breaks with a potty training 3 year old) later, we left with empty bellies, frustration, and PICTURES. Continue reading